Table 1. Baseline Clinical Characteristics of Patients Across Treated and Control Groups in the Overall Data Set, the Training Subset, and the Testing Subset.
| Baseline Covariate | Overall | Training Data | Testing Data | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | P Value | Mean (SD) | P Value | Mean (SD) | P Value | ||||
| Treated | Control | Treated | Control | Treated | Control | ||||
| Framingham estimation of 10-y CVD risk, points | 20.1 (10.9) | 20.2 (10.8) | .83 | 20.2 (10.5) | 20.1 (10.9) | .22 | 20.1 (11.3) | 20.2 (10.6) | .36 |
| Current smoker, No. (%) | 615 (13.3) | 651 (13.9) | .27 | 296 (12.6) | 323 (13.9) | .18 | 319 (13.7) | 328 (13.9) | .83 |
| Blood pressure, mm Hg | |||||||||
| Systolic | 139.7 (15.7) | 139.7 (15.5) | .96 | 140.0 (16.0) | 139.5 (15.4) | .88 | 139.4 (15.5) | 140.0 (15.7) | .94 |
| Diastolic | 78.2 (11.9) | 78.1 (12.1) | .47 | 78.3 (12.2) | 77.9 (11.9) | .77 | 78.2 (11.6) | 78.3 (12.3) | .48 |
| Daily aspirin use, No. (%) | 2406 (50.8) | 2350 (51.4) | .23 | 1208 (51.1) | 1185 (52.0) | .24 | 1198 (50.5) | 1165 (50.9) | .59 |
| eGFR MDRD, mL/min/1.73m2 | 71.7 (20.7) | 71.7 (20.7) | .92 | 71.5 (20.5) | 71.1 (20.6) | .47 | 71.8 (20.9) | 72.4 (20.8) | .56 |
| Serum creatinine, mg/dL | 1.1 (0.35) | 1.1 (0.34) | .73 | 1.1 (0.34) | 1.1 (0.34) | .27 | 1.1 (0.35) | 1.1 (0.34) | .56 |
| Black or African American, No. (%) | 1493 (31.9) | 1454 (31.1) | .40 | 754 (32.0) | 744 (32.0) | .99 | 739 (31.8) | 710 (30.2) | .23 |
| Age at randomization top-coded at 90 y, y | 67.9 (9.4) | 67.9 (9.5) | .94 | 68.1 (9.4) | 67.8 (9.4) | .50 | 67.7 (9.4) | 68.0 (9.6) | .43 |
| Female, No. (%) | 1648 (35.2) | 1684 (36.0) | .41 | 804 (34.1) | 859 (37.0) | .04 | 844 (36.3) | 825 (35.1) | .38 |
| Cholesterol, mg/dL | 190.4 (40.7) | 189.6 (40.6) | .85 | 190.0 (41.9) | 190.3 (41.4) | .66 | 190.8 (41.5) | 188.8 (39.7) | .87 |
| Glucose, mg/dL | 98.9 (13.8) | 98.9 (13.4) | .86 | 98.9 (13.3) | 98.8 (13.7) | .68 | 98.9 (14.3) | 99.0 (13.1) | .51 |
| HDL-C direct, mg/dL | 52.9 (14.4) | 52.7 (14.6) | .66 | 52.6 (14.2) | 52.7 (15.0) | .54 | 53.1 (14.3) | 52.8 (13.1) | .20 |
| Triglycerides, mg/dL | 125.6 (87.1) | 126.6 (80.9) | .22 | 125.3 (92.2) | 127.1 (83.3) | .54 | 125.8 (81.6) | 126.1 (78.4) | .24 |
| Urine albumin in mg/(creatinine in g × 0.01) | 43.7 (178.4) | 41.3 (154.2) | .39 | 43.0 (150.8) | 41.8 (135.3) | .57 | 44.3 (202.2) | 40.9 (171.1) | .52 |
| BMI | 29.9 (5.8) | 29.8 (5.74) | .39 | 30.0 (5.9) | 29.9 (5.6) | .14 | 29.9 (5.8) | 29.7 (5.9) | .77 |
| Receiving any statin, No. (%) | 2076 (44.3) | 1978 (42.3) | .04 | 1065 (45.2) | 986 (42.4) | .05 | 1011 (43.5) | 992 (42.1) | .32 |
Abbreviations: BMI body mass index (calculated as weight in kilograms divided by height in meters squared); CVD, cardiovascular disease; eGFR, epidermal growth factor receptor; HDL-C, high-density lipoprotein cholesterol; MDRD, Modification of Diet in Renal Disease.
SI conversion factors: To convert serum creatinine to micromoles per liter, multiply by 88.4; glucose to millimoles per liter, multiply by 0.0555; triglycerides to millimoles per liter, multiply by 0.113; and total cholesterol and HDL-C to millimoles per liter, multiply by 0.0259.